Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating

Tectonic Therapeutic, Inc. (NASDAQ:TECX) is one of the Best Micro-Cap Stocks to Invest in According to Analysts.

Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating

Stocks chart

On November 18, LifeSci Capital reiterated a Buy rating on Tectonic Therapeutic, Inc. (NASDAQ:TECX) stock with a price target of $88. Tectonic Therapeutic, Inc. (NASDAQ:TECX) is a biotechnology company that focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors.

Tectonic Therapeutic, Inc. (NASDAQ:TECX) develops the GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. One of the lead product candidates of the firm is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia, a GPCR modulator bispecific for treating fibrosis, and other GPCR modulators.

While we acknowledge the potential of TECX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TECX and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 15 Dividend Stocks Paying 4%+ Yield in 2025 and 14 Best US Stocks to Buy for Long Term

Disclosure: None.